Description

QuidelOrtho Corporation: Its Diverse Revenue Streams Surge – Discover the Lab Innovations Powering Growth!

QuidelOrtho’s third quarter 2024 financial results reveal a mixed performance, characterized by challenges and opportunities that investors should carefully weigh. The reported revenue for the quarter stood at $727 million, a roughly 2% decline from the previous year, influenced by a decrease in COVID-19 and flu-related revenues compared to the prior year. The company’s adjusted EBITDA was $171 million, translating to an adjusted EBITDA margin of 23.5%, showing an improvement of 80 basis points over the previous year, primarily due to implemented cost-saving measures. Adjusted diluted earnings per share were reported at $0.85.

Our Report Structure:

⦁ Company Overview
⦁ Investment Thesis
⦁ Key Drivers
⦁ Historical Quarterly Statement Analysis – Income Statement & Cash Flows
⦁ Historical Quarterly Balance Sheet Analysis
⦁ Historical Annual Financial Statement Analysis
⦁ Analysis Of Key Financial Ratios
⦁ Financial Forecasts For 3 Years
⦁ Forecasting The Capital Structure & Net Debt
⦁ Discounted Cash Flow Valuation
⦁ Trading Multiples
⦁ Key Risks
⦁ Disclosures

Want unlimited access to our reports? Purchase our $99 annual subscription!